TOP TEN perturbations for NP_689504 (Homo sapiens)

Organism: Homo sapiens
Gene: NP_689504
Selected probe(set): 217059_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NP_689504 (217059_at) across 6593 perturbations tested by GENEVESTIGATOR:

basal cell carcinoma study 3 / normal epidermal keratinocytes

Relative Expression (log2-ratio):5.4158
Number of Samples:4 / 2
Experimental basal cell carcinoma study 3
Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC).
Control normal epidermal keratinocytes
Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37°C in humidified air containing 5% CO2.

trachoma study 1 (C. trachomatis positive) / normal tarsal conjunctiva tissue

Relative Expression (log2-ratio):-4.777673
Number of Samples:18 / 20
Experimental trachoma study 1 (C. trachomatis positive)
Swabs from the tarsal conjunctiva of patients with clinical signs of acute trachoma and infection with Chlamydia trachomatis.
Control normal tarsal conjunctiva tissue
Swabs from the tarsal conjunctiva of subjects without clinical signs of active trachoma in both eyes and absence of C. trachomatis infection.

cutaneous sarcoidosis study 1 (lesional) / normal skin tissue

Relative Expression (log2-ratio):-4.2748766
Number of Samples:13 / 5
Experimental cutaneous sarcoidosis study 1 (lesional)
Lesional skin biopsies from patients with acute cutaneous sarcoidosis.
Control normal skin tissue
Skin biopsy samples from healthy control subjects.

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):3.840992
Number of Samples:2 / 13
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).

psoriasis study 24 (lesional; baseline; etarnecept; non-responder) / psoriasis study 24 (non-lesional; baseline; etarnecept; non-responder)

Relative Expression (log2-ratio):-3.6215262
Number of Samples:13 / 13
Experimental psoriasis study 24 (lesional; baseline; etarnecept; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; etarnecept; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

chronic rhinosinusitis study 1 / normal nasal cavity epithelium sample

Relative Expression (log2-ratio):3.2591906
Number of Samples:9 / 9
Experimental chronic rhinosinusitis study 1
Nasal cavity epithelium from patients with chronic rhinosinusitis.
Control normal nasal cavity epithelium sample
Normal nasal cavity epithelium.

trachoma study 1 (C. trachomatis negative) / normal tarsal conjunctiva tissue

Relative Expression (log2-ratio):-3.2414837
Number of Samples:22 / 20
Experimental trachoma study 1 (C. trachomatis negative)
Swabs from the tarsal conjunctiva of patients with clinical signs of acute trachoma but without detectable Chlamydia trachomatis infection.
Control normal tarsal conjunctiva tissue
Swabs from the tarsal conjunctiva of subjects without clinical signs of active trachoma in both eyes and absence of C. trachomatis infection.

psoriasis study 25 (lesional; baseline; etarnecept; non-responder) / psoriasis study 25 (non-lesional; baseline; etarnecept; non-responder)

Relative Expression (log2-ratio):-3.233922
Number of Samples:14 / 13
Experimental psoriasis study 25 (lesional; baseline; etarnecept; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; etarnecept; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with etarnecept) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)

Relative Expression (log2-ratio):-3.0566187
Number of Samples:22 / 23
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 25 (lesional; baseline; ustekinumab; responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)

Relative Expression (log2-ratio):-3.0216322
Number of Samples:22 / 23
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.